Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.

ABSTRACT:

Aims

Heart failure with reduced ejection fraction (HFrEF) is associated with excessive sympathetic and impaired parasympathetic activity. The Barostim Neo™ device is used for electronical baroreflex activation therapy (BAT) to counteract autonomic nervous system dysbalance. Randomized trials have shown that BAT improves walking distance and reduces N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels at least in patients with only moderate elevation at baseline. Its impact on the risk of heart failure hospitalization (HFH) and death is not yet established, and experience in clinical routine is limited.

Methods and results

We report on patient characteristics and clinical outcome in a retrospective, non-randomized single-centre registry of BAT in HFrEF. Patie

SUBMITTER: Blanco C 

PROVIDER: S-EPMC10682889 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature